爱德华生命科学 EW
$102.14 +$1.32 (+1.31%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $102.14 0.00%
开盘$99.00
昨收$100.82
当日区间$98.50 – $102.19
成交量5.11M
市值$58.73B
市盈率（TTM）57.7
股息率–
财报
财报日平均波动±6.8%近16次财报
收涨次数6 / 1638% 的概率
最佳反应+6.9%
最差反应-31.3%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q2 | 23 Jul 2026 | After Market | ±9.5% | -1.42% | 符合区间 |
| 2026/Q1 | 23 Apr 2026 | After Market | ±8.7% | +5.56% | 符合区间 |
| 2025/Q4 | 10 Feb 2026 | After Market | ±7.2% | +2.96% | 符合区间 |
| 2025/Q3 | 30 Oct 2025 | After Market | ±6.6% | -1.23% | 符合区间 |
| 2025/Q2 | 24 Jul 2025 | After Market | ±9.5% | +5.54% | 符合区间 |
| 2025/Q1 | 23 Apr 2025 | After Market | ±10.0% | +6.63% | 符合区间 |
| 2024/Q4 | 11 Feb 2025 | After Market | ±7.4% | +6.92% | 符合区间 |
| 2024/Q3 | 24 Oct 2024 | After Market | ±11.2% | -1.38% | 符合区间 |
| 2024/Q2 | 24 Jul 2024 | After Market | ±7.9% | -31.34% | 超出定价预期 |
| 2024/Q1 | 25 Apr 2024 | After Market | ±7.8% | -1.80% | 符合区间 |
| 2023/Q4 | 6 Feb 2024 | After Market | ±7.6% | -1.86% | 符合区间 |
| 2023/Q3 | 25 Oct 2023 | After Market | ±11.0% | -8.14% | 符合区间 |
| 2023/Q2 | 26 Jul 2023 | After Market | ±6.2% | -9.78% | 超出定价预期 |
| 2023/Q1 | 26 Apr 2023 | After Market | ±10.2% | -0.79% | 符合区间 |
| 2022/Q4 | 31 Jan 2023 | After Market | ±5.5% | +6.23% | 超出定价预期 |
| 2022/Q3 | 27 Oct 2022 | After Market | ±6.8% | -17.88% | 超出定价预期 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
营收构成
2026/Q2 季度
按业务线
基本面
最新报告季度：Q2, ended Jun 2026
营收$1.74B+13.6% YoY
营业利润$519.50M+20.6% YoY
净利润$241.40M-27.2% YoY
摊薄每股收益$0.42-25.0% YoY
自由现金流$585.00M+142.8% YoY
经营现金流$651.90M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率77.8%
营业利润率28.1%
净利率15.4%
净资产收益率9.5%
资产收益率7.3%
投入资本回报率7.9%
流动比率4.52
负债/资产比率22.7%
现金及投资$4.25B
总负债$680.30M
净现金（净负债）$3.57B
自由现金流/营收22.0%
暂无评论——快来第一个聊聊 EW。